Supreme Court Says State Law Design Defect Claim For Generic Drug Is Preempted

WASHINGTON, D.C. - (Mealey's) In a 5-4 decision, the U.S. Supreme Court on June 24 ruled that state law design defect claims that turn on the adequacy of a drug's warning are preempted by federal law ( Mutual Pharmaceutical Company, Inc. v. Karen L. Bartlett , No. 12-142, U.S. Sup.). [